Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with Tolvaptan

Paul J. Hauptman, John C Jr. Burnett, Mihai Gheorghiade, Liliana Grinfeld, Marvin A. Konstam, Dusan Kostic, Holly B. Krasa, Aldo Maggioni, John Ouyang, Karl Swedberg, Faiez Zannad, Chris Zimmer, James E. Udelson

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Background: Patients with decompensated heart failure, volume overload, and hyponatremia are challenging to manage. Relatively little has been documented regarding the clinical course of these patients during standard in-hospital management or with vasopressin antagonism. Methods and Results: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes. In the placebo group, patients with hyponatremia (serum Na+ <135mEq/L; n = 232), compared with those with normonatremia at baseline (n = 1785), had less relief of dyspnea despite receiving higher doses of diuretics (59.2% vs 69.2% improved; P <.01) and worse long-term outcomes. In the hyponatremia subgroup from the entire trial cohort (n = 475), tolvaptan was associated with greater likelihood of normalization of serum sodium than placebo (58% vs 20% and 64% vs 29% for day 1 and discharge, respectively; P <.001 for both comparisons), greater weight reduction at day 1 and discharge (0.7 kg and 0.8 kg differences, respectively; P <.001 and P =.008), and greater relief of dyspnea (P =.03). Among all hyponatremic patients, there was no effect of tolvaptan on long-term outcomes compared with placebo. In patients with pronounced hyponatremia (<130 mEq/L; n = 92), tolvaptan was associated with reduced cardiovascular morbidity and mortality after discharge (P =.04). Conclusions: In patients with decompensated heart failure and hyponatremia, standard therapy is associated with less weight loss and dyspnea relief, and unfavorable longer-term outcomes compared to those with normonatremia. Tolvaptan is associated with more favorable in-hospital effects and, possibly, long-term outcomes in patients with severe hyponatremia.

Original languageEnglish (US)
Pages (from-to)390-397
Number of pages8
JournalJournal of Cardiac Failure
Volume19
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Systolic Heart Failure
Vasopressin Receptors
Hyponatremia
Heart Failure
Dyspnea
Placebos
Vasopressins
Weight Loss
Cardiac Volume
tolvaptan
Serum
Diuretics
Curriculum
Sodium
Outcome Assessment (Health Care)
Databases
Morbidity
Mortality

Keywords

  • Heart failure
  • hyponatremia
  • prognosis
  • vasopressin antagonist

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with Tolvaptan. / Hauptman, Paul J.; Burnett, John C Jr.; Gheorghiade, Mihai; Grinfeld, Liliana; Konstam, Marvin A.; Kostic, Dusan; Krasa, Holly B.; Maggioni, Aldo; Ouyang, John; Swedberg, Karl; Zannad, Faiez; Zimmer, Chris; Udelson, James E.

In: Journal of Cardiac Failure, Vol. 19, No. 6, 06.2013, p. 390-397.

Research output: Contribution to journalArticle

Hauptman, PJ, Burnett, JCJ, Gheorghiade, M, Grinfeld, L, Konstam, MA, Kostic, D, Krasa, HB, Maggioni, A, Ouyang, J, Swedberg, K, Zannad, F, Zimmer, C & Udelson, JE 2013, 'Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with Tolvaptan', Journal of Cardiac Failure, vol. 19, no. 6, pp. 390-397. https://doi.org/10.1016/j.cardfail.2013.04.001
Hauptman, Paul J. ; Burnett, John C Jr. ; Gheorghiade, Mihai ; Grinfeld, Liliana ; Konstam, Marvin A. ; Kostic, Dusan ; Krasa, Holly B. ; Maggioni, Aldo ; Ouyang, John ; Swedberg, Karl ; Zannad, Faiez ; Zimmer, Chris ; Udelson, James E. / Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with Tolvaptan. In: Journal of Cardiac Failure. 2013 ; Vol. 19, No. 6. pp. 390-397.
@article{9a1bc81ef30b4d1d9c72edd1bbb78f90,
title = "Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with Tolvaptan",
abstract = "Background: Patients with decompensated heart failure, volume overload, and hyponatremia are challenging to manage. Relatively little has been documented regarding the clinical course of these patients during standard in-hospital management or with vasopressin antagonism. Methods and Results: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes. In the placebo group, patients with hyponatremia (serum Na+ <135mEq/L; n = 232), compared with those with normonatremia at baseline (n = 1785), had less relief of dyspnea despite receiving higher doses of diuretics (59.2{\%} vs 69.2{\%} improved; P <.01) and worse long-term outcomes. In the hyponatremia subgroup from the entire trial cohort (n = 475), tolvaptan was associated with greater likelihood of normalization of serum sodium than placebo (58{\%} vs 20{\%} and 64{\%} vs 29{\%} for day 1 and discharge, respectively; P <.001 for both comparisons), greater weight reduction at day 1 and discharge (0.7 kg and 0.8 kg differences, respectively; P <.001 and P =.008), and greater relief of dyspnea (P =.03). Among all hyponatremic patients, there was no effect of tolvaptan on long-term outcomes compared with placebo. In patients with pronounced hyponatremia (<130 mEq/L; n = 92), tolvaptan was associated with reduced cardiovascular morbidity and mortality after discharge (P =.04). Conclusions: In patients with decompensated heart failure and hyponatremia, standard therapy is associated with less weight loss and dyspnea relief, and unfavorable longer-term outcomes compared to those with normonatremia. Tolvaptan is associated with more favorable in-hospital effects and, possibly, long-term outcomes in patients with severe hyponatremia.",
keywords = "Heart failure, hyponatremia, prognosis, vasopressin antagonist",
author = "Hauptman, {Paul J.} and Burnett, {John C Jr.} and Mihai Gheorghiade and Liliana Grinfeld and Konstam, {Marvin A.} and Dusan Kostic and Krasa, {Holly B.} and Aldo Maggioni and John Ouyang and Karl Swedberg and Faiez Zannad and Chris Zimmer and Udelson, {James E.}",
year = "2013",
month = "6",
doi = "10.1016/j.cardfail.2013.04.001",
language = "English (US)",
volume = "19",
pages = "390--397",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with Tolvaptan

AU - Hauptman, Paul J.

AU - Burnett, John C Jr.

AU - Gheorghiade, Mihai

AU - Grinfeld, Liliana

AU - Konstam, Marvin A.

AU - Kostic, Dusan

AU - Krasa, Holly B.

AU - Maggioni, Aldo

AU - Ouyang, John

AU - Swedberg, Karl

AU - Zannad, Faiez

AU - Zimmer, Chris

AU - Udelson, James E.

PY - 2013/6

Y1 - 2013/6

N2 - Background: Patients with decompensated heart failure, volume overload, and hyponatremia are challenging to manage. Relatively little has been documented regarding the clinical course of these patients during standard in-hospital management or with vasopressin antagonism. Methods and Results: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes. In the placebo group, patients with hyponatremia (serum Na+ <135mEq/L; n = 232), compared with those with normonatremia at baseline (n = 1785), had less relief of dyspnea despite receiving higher doses of diuretics (59.2% vs 69.2% improved; P <.01) and worse long-term outcomes. In the hyponatremia subgroup from the entire trial cohort (n = 475), tolvaptan was associated with greater likelihood of normalization of serum sodium than placebo (58% vs 20% and 64% vs 29% for day 1 and discharge, respectively; P <.001 for both comparisons), greater weight reduction at day 1 and discharge (0.7 kg and 0.8 kg differences, respectively; P <.001 and P =.008), and greater relief of dyspnea (P =.03). Among all hyponatremic patients, there was no effect of tolvaptan on long-term outcomes compared with placebo. In patients with pronounced hyponatremia (<130 mEq/L; n = 92), tolvaptan was associated with reduced cardiovascular morbidity and mortality after discharge (P =.04). Conclusions: In patients with decompensated heart failure and hyponatremia, standard therapy is associated with less weight loss and dyspnea relief, and unfavorable longer-term outcomes compared to those with normonatremia. Tolvaptan is associated with more favorable in-hospital effects and, possibly, long-term outcomes in patients with severe hyponatremia.

AB - Background: Patients with decompensated heart failure, volume overload, and hyponatremia are challenging to manage. Relatively little has been documented regarding the clinical course of these patients during standard in-hospital management or with vasopressin antagonism. Methods and Results: The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan database was examined to assess the short-term clinical course of patients hospitalized with heart failure and hyponatremia and the effect of tolvaptan on outcomes. In the placebo group, patients with hyponatremia (serum Na+ <135mEq/L; n = 232), compared with those with normonatremia at baseline (n = 1785), had less relief of dyspnea despite receiving higher doses of diuretics (59.2% vs 69.2% improved; P <.01) and worse long-term outcomes. In the hyponatremia subgroup from the entire trial cohort (n = 475), tolvaptan was associated with greater likelihood of normalization of serum sodium than placebo (58% vs 20% and 64% vs 29% for day 1 and discharge, respectively; P <.001 for both comparisons), greater weight reduction at day 1 and discharge (0.7 kg and 0.8 kg differences, respectively; P <.001 and P =.008), and greater relief of dyspnea (P =.03). Among all hyponatremic patients, there was no effect of tolvaptan on long-term outcomes compared with placebo. In patients with pronounced hyponatremia (<130 mEq/L; n = 92), tolvaptan was associated with reduced cardiovascular morbidity and mortality after discharge (P =.04). Conclusions: In patients with decompensated heart failure and hyponatremia, standard therapy is associated with less weight loss and dyspnea relief, and unfavorable longer-term outcomes compared to those with normonatremia. Tolvaptan is associated with more favorable in-hospital effects and, possibly, long-term outcomes in patients with severe hyponatremia.

KW - Heart failure

KW - hyponatremia

KW - prognosis

KW - vasopressin antagonist

UR - http://www.scopus.com/inward/record.url?scp=84878580083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878580083&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2013.04.001

DO - 10.1016/j.cardfail.2013.04.001

M3 - Article

C2 - 23743487

AN - SCOPUS:84878580083

VL - 19

SP - 390

EP - 397

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 6

ER -